Scholarlink

<p>Thyroid hormone receptor interacting protein 13 (TRIP13), a versatile protein, has gained prominence for its role in mitotic checkpoint complex inactivation and participation in various cellular processes. Its association with human cancers, impacting progression, apoptosis, and signaling pathways, highlighted its multifaceted role. However, there was currently no comprehensive analysis to assess the clinical value of TRIP13 in cancer patients. Eligible studies were identified through searches on online English databases. The assessment of TRIP13’s role in cancers involved the pooling of hazard ratios (HR) and odds ratios (OR). This meta-analysis systematically investigated TRIP13’s clinical significance across 12 studies, encompassing 11 cancer types. Elevated TRIP13 expression emerged as an effective prognostic marker, correlating with poorer overall survival (pooled HR = 1.889, 95% CI = 1.639–2.178), lymph node metastasis, distant metastasis, and advanced TNM stage (<i>P</i> &lt; 0.001). Subgroup analyses underscored its significance in digestive and urinary system cancers (<i>P</i> &lt; 0.001). The absence of heterogeneity and publication bias enhanced result reliability. This meta-analysis, the first of its kind, provided valuable insights into TRIP13’s prognostic and clinicopathological implications, establishing it as a potential therapeutic target in cancer intervention.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Prognostic Significance and Clinicopathological Impact of TRIP13 Across Various Cancers: A Comprehensive Meta-analysis

  • 期刊论文

  • 发表日期：

    2025年1月7日

查看全文
  • Chunyan Meng,
  • Jingting Liu,
  • Jun Cheng,
  • Baoqing Liu,
  • Jianhua Liao

摘要

Thyroid hormone receptor interacting protein 13 (TRIP13), a versatile protein, has gained prominence for its role in mitotic checkpoint complex inactivation and participation in various cellular processes. Its association with human cancers, impacting progression, apoptosis, and signaling pathways, highlighted its multifaceted role. However, there was currently no comprehensive analysis to assess the clinical value of TRIP13 in cancer patients. Eligible studies were identified through searches on online English databases. The assessment of TRIP13’s role in cancers involved the pooling of hazard ratios (HR) and odds ratios (OR). This meta-analysis systematically investigated TRIP13’s clinical significance across 12 studies, encompassing 11 cancer types. Elevated TRIP13 expression emerged as an effective prognostic marker, correlating with poorer overall survival (pooled HR = 1.889, 95% CI = 1.639–2.178), lymph node metastasis, distant metastasis, and advanced TNM stage (P < 0.001). Subgroup analyses underscored its significance in digestive and urinary system cancers (P < 0.001). The absence of heterogeneity and publication bias enhanced result reliability. This meta-analysis, the first of its kind, provided valuable insights into TRIP13’s prognostic and clinicopathological implications, establishing it as a potential therapeutic target in cancer intervention.